Sanofi Exec says not Scrimp in Biotechs’s clinical test design

At a time, some companies have to reduce the number of patients or changing time and change the test designs, they should have made decisions to change the test designs.

Fireside Chat in May 5-6, May 5-6, May 5-6, Houmer Ashrafian, Executive and Development and Development (R & D), which seems goodbye to last a company for a longer term, it can even even lower the company.

“Don’t mix the clinical test. Critically important … It will kill him very quickly with your asset.” In some trial failure, an additional $ 3-4 million investment can lead to an additional $ 3-4 million to strengthen and effectively manage trials. “Recently, the P-value declared the tests within a value of 0.07 and made the stock prices.

While some companies struggle to balance their finances, Ashrafi, like some companies, 2021 Booms, biotechnics, biotechnics, which have been a completely negative thing that has been a completely negative thing since 2021.

“Better and better financing of biotechnics and some are the definition of madness that you have saved yourself.

Sanofi has a Venture Capital (VC) Biotechnics financing goals to use clinical trials. Ashrafi invited to ensure the most effective trial to develop biotech companies, and then a pharmaceutical company was able to get the latest development.

“Biotechnics produces molecules at a significant discount on Pharma. Chemistry, production and control (CMC) may not be good, but biotechnic (companies) receive a molecule in this beautiful way.